Gilder Gagnon Howe & Co’s Kite Pharma, Inc. KITE Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio KITE Stock Details KITE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-8,851	Closed	-$918K	–	311
2017 Q2	$918K	Sell	8,851 -1,465	-14%	-$120K	0.01%	205
2017 Q1	$810K	Buy	+10,316	New	+$638K	0.01%	199
2015 Q2	–	Sell	-48,924	Closed	-$2.82M	–	305
2015 Q1	$2.82M	Sell	48,924 -37,467	-43%	-$2.51M	0.04%	162
2014 Q4	$4.98M	Buy	+86,391	New	+$3.64M	0.07%	145

Other funds holding KITE

Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCSAM

Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Gilder Gagnon Howe & Co's KITE Position: Q3 2017 in Review

Gilder Gagnon Howe & Co sold out of Kite Pharma, Inc. (KITE) in Q3 2017, closing a stake of 8,851 shares — an estimated $918K sold.

Gilder Gagnon Howe & Co first reported a position in KITE in Q4 2014 and held it in 4 quarters. The position peaked at $4.98M in Q4 2014. 244 funds tracked by Wall St. Rank hold KITE as of Q3 2017.

Gilder Gagnon Howe & Co reported no remaining Kite Pharma, Inc. position as of Q3 2017 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 8,851 Kite Pharma, Inc. shares in Q3 2017, an estimated $918K.
Gilder Gagnon Howe & Co first reported a position in Kite Pharma, Inc. in Q4 2014 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Kite Pharma, Inc. position peaked at $4.98M in Q4 2014.
244 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q3 2017.

Based on Gilder Gagnon Howe & Co's 13F filing for Q3 2017, filed 6 Nov 2017.